FDA Shakeup Elevates Kyle Diamantas and Sparks Questions for Food Industry – Image for illustrative purposes only (Image credits: Pexels)
A 37-year-old corporate lawyer with close ties to the Trump family has taken the helm at the Food and Drug Administration as acting commissioner. Kyle Diamantas steps into the role after the sudden resignation of Marty Makary, who led the agency for just over a year. The move comes at a time when the FDA faces ongoing questions about drug approvals, food safety oversight, and regulatory priorities under the current administration.
Why Makary Stepped Down
Makary’s departure followed repeated clashes with White House officials and members of Congress. Disputes centered on access to abortion medications, the handling of fruit-flavored vapes favored by adult consumers, and repeated rejections of treatments for rare diseases. His time in charge also included large-scale staff reductions and repeated turnover among senior officials.
Critics argued that these decisions slowed the introduction of new therapies. Ross Marchand, executive director of the Taxpayers Protection Alliance, said millions of Americans had suffered from inconsistent approval processes and shifting standards. The agency now needs steady leadership focused on patient access, he added.
Background on the New Acting Head
Diamantas previously served as deputy commissioner for food and has no medical training. His legal career includes work representing Abbott Laboratories during its infant formula recall litigation. He earned his law degree from the University of Florida and has appeared at public events promoting administration health initiatives in recent weeks.
Inside the agency, colleagues describe him as a low-key choice who has kept senior staff in place. President Trump called him a “very talented person” in a social media post. The selection surprised some observers because Diamantas lacks direct experience in food safety enforcement or public health policy.
Key Areas Under His Control
As the top food policy official, Diamantas now oversees resource allocation, emergency response, and day-to-day food-safety operations. One immediate challenge involves developing a clear definition for ultra-processed foods, an issue Health and Human Services Secretary Robert F. Kennedy Jr. has highlighted as a driver of chronic disease.
The agency must also address long-standing backlogs in product reviews. Earlier tensions over nicotine products and vaccine policy added to the pressure. Diamantas will need to balance these demands while maintaining continuity in leadership.
Industry and Stakeholder Reactions
Tobacco companies and related retailers welcomed the change. Laura Leigh Oyler, vice president of regulatory affairs at Nicokick.com, said the FDA had moved too slowly on nicotine product reviews. She called the leadership shift an opportunity to restore timely, evidence-based decisions that serve adult consumers and responsible manufacturers.
Food industry groups are watching closely for signs of policy shifts. Some worry that limited public health experience at the top could affect enforcement priorities. Others see the appointment as a chance to reduce regulatory uncertainty that has built up over the past year.
What Comes Next
The White House has begun searching for a permanent commissioner. In the meantime, Diamantas will manage daily operations and ongoing initiatives. His background in regulatory compliance may help stabilize internal processes, though questions remain about how quickly he can address broader food safety and innovation concerns.
Stakeholders across the food and drug sectors will track early decisions for clues about the agency’s direction. The coming months will test whether the new leadership can restore confidence while advancing the administration’s stated goals.
